The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements
- First Online:
- 139 Downloads
As cognitive impairments are related to deficits in everyday functioning in schizophrenia, treatment of these impairments may have the potential to reduce these functional deficits. To determine if treatments truly reduce cognitive impairment, it is important to discriminate direct cognitive effects of treatment from generalized treatment benefits on the multiple clinical dimensions of schizophrenia. Thus, this study used a database from an existing clinical trial and examined the relationships between changes in clinical symptoms and cognitive deficits with several different strategies.
Materials and methods
Two hundred and seventy stable but symptomatic outpatients with schizophrenia entered a study where they were switched from previous treatment to open-label ziprasidone. The present data are from the 6-month endpoint (n=184). Patients were examined at baseline and the 6-month endpoint with ratings of clinical symptoms based on the Positive and Negative Syndrome Scale (PANSS) and a neuropsychological (NP) assessment battery including aspects of cognitive functioning known to be related to functional outcome in schizophrenia.
Changes on the individual PANSS items and NP test scores were examined with two separate principal components analyses, revealing four dimensions of clinical change (psychosis, negative symptoms, affective symptoms, and agitation) and two dimensions of NP improvement. Pearson correlations between changes in the (1) factors derived from the analyses, (2) individual NP items based the four clinical dimensions of change, and (3) the 30 PANSS items and the two NP dimensions of change suggested minimal relationships (largest r=0.15).
This sample was selected because previous findings suggested that clinical and NP symptoms of schizophrenia significantly improved from baseline after a switch to ziprasidone treatment. While four dimensions of change in clinical symptoms and two dimensions of cognitive improvements were identified, clinical changes, regardless of how they were defined, were not related to NP improvements.
KeywordsSchizophrenia Clinical effectiveness Cognitive function Antipsychotic Treatment
- Blyler CR, Gold JM (2000) Cognitive effects of typical antipsychotic medication treatment: another look. In: Sharma T, Harvey PD (eds) Cognition in schizophrenia. Oxford University Press, Oxford, London, UK, pp 241–265Google Scholar
- Chouinard G, Ross-Chouinard A et al (1980) Extrapyramidal symptom rating scale. Can J Neurol Sci 7:233Google Scholar
- Heaton RK, Chellune CJ, Talley JL, Kay GG, Curtiss G (1993) Wisconsin Card Sorting Test Manual—revised and expanded. Psychological Assessment Resources, Odessa, FLGoogle Scholar
- Kay SR (1991) Positive and negative syndromes in schizophrenia. Brunner/Mazel, New YorkGoogle Scholar
- Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985–995PubMedCrossRefGoogle Scholar
- Keefe RSE, Bilder RM, Harvey PD et al (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, in pressGoogle Scholar
- Kurt MM, Moberg PJ, Gur RC, Gur RE (2001) Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol Rev 11:197–210Google Scholar
- Reitan RM, Wolfson D (1993) The Halstead–Reitan neuropsychological test battery: theory and clinical interpretation, 2nd edn. Neuropsychology Press, Tucson, AZGoogle Scholar
- Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837–1847PubMedCrossRefGoogle Scholar
- Spreen O, Strauss EA (1998) compendium of neuropsychological tests and norms, 2nd edn. New York, Oxford University Press, London, UKGoogle Scholar
- Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363–1373Google Scholar
- White L, Harvey PD, Opler L, Lindenmayer JP (1997) Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 30(5):263–274PubMedCrossRefGoogle Scholar